Hemochromatosis Type 4 C1853733
Hemochromatosis Type 4 is a genetic condition where the body cannot properly regulate iron absorption and storage. It leads to iron buildup in various organs. Management may include phlebotomy and dietary adjustments.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(metabolic)Fatigue or weight changes
(metabolic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Arthralgia
(metabolic)Anemia
(metabolic)Bone pain
(metabolic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Therapeutic phlebotomy
Regular removal of blood to reduce iron overload in the body. The procedure involves drawing 400-500mL of blood at intervals determined by iron levels.
Iron chelation therapy
Use of chelating agents that bind to excess iron in the blood for elimination. Reserved for patients unable to tolerate phlebotomy.
Additional treatment options
Iron-restricted diet
Dietary modifications to limit iron intake including avoiding red meat, iron-fortified foods, and excessive vitamin C which enhances iron absorption.
dietaryIron studies monitoring
Regular blood testing to monitor serum ferritin, transferrin saturation, and liver iron concentration to guide treatment intensity.
monitoringAlcohol avoidance
Complete abstinence from alcohol to prevent additional liver damage in patients with iron overload affecting hepatic tissue.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Hemochromatosis Type 4 C1853733?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Pietrangelo A, Roetto A, Calì A. Non-HFE hemochromatosis: genetics and clinical outcomes. Gastroenterology. 2019.
Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011.
McDonald CJ, Wallace DF, Crawford DH, Subramaniam VN. Ferroportin disease: a systematic review. Hepatology. 2018.
Van Wagoner DR, Boiger J, Schilsky ML. Clinical manifestations of ferroportin (SLC40A1) mutations: a genotype-phenotype study. Blood. 2020.
Medication Comparisons
Compare medications used to treat Hemochromatosis Type 4 C1853733. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy